Sustained Activation of JNK/p38 MAPK Pathways in Response to Cisplatin Leads to Fas Ligand Induction and Cell Death in Ovarian Carcinoma Cells*

The efficacy of cisplatin in cancer chemotherapy is limited by the development of resistance. Although the molecular mechanisms involved in chemoresistance are poorly understood, cellular response to cisplatin is known to involve activation of MAPK and other signal transduction pathways. An understanding of early signal transduction events in the response to cisplatin could be valuable for improving the efficacy of cancer therapy. We compared cisplatin-induced activation of three MAPKs, JNK, p38, and ERK, in a cisplatin-sensitive human ovarian carcinoma cell line (2008) and its resistant subclone (2008C13). The JNK and p38 pathways were activated differentially in response to cisplatin, with the cisplatin-sensitive cells showing prolonged activation (8–12 h) and the cisplatin-resistant cells showing only transient activation (1–3 h) of JNK and p38. In the sensitive cells, inhibition of cisplatin-induced JNK and p38 activation blocked cisplatin-induced apoptosis; persistent activation of JNK resulted in hyperphosphorylation of the c-Jun transcription factor, which in turn stimulated the transcription of an immediate downstream target, the death inducer Fas ligand (FasL). Sequestration of FasL by incubation with a neutralizing anti-FasL antibody inhibited cisplatin-induced apoptosis. In contrast, chemoresistance in 2008C13 cells was associated with failure to up-regulate FasL. Moreover, in these cells, selective stimulation of the JNK/p38 MAPK pathways by adenovirus-mediated delivery of recombinant MKK7 or MKK3 led to sensitization to apoptosis through reactivating FasL expression. Thus, the JNK > c-Jun > FasL > Fas pathway plays an important role in mediating cisplatin-induced apoptosis in ovarian cancer cells, and the duration of JNK activation is critical in determining whether cells survive or undergo apoptosis.

[1]  S. Howell,et al.  Short-termcis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells , 2004, Cancer Chemotherapy and Pharmacology.

[2]  G. Kucera,et al.  c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for mitoxantrone- and anisomycin-induced apoptosis in HL-60 cells. , 2002, Leukemia research.

[3]  X. Lin,et al.  Identification of genes that mediate sensitivity to cisplatin. , 2001, Molecular pharmacology.

[4]  I. Herr,et al.  Cellular stress response and apoptosis in cancer therapy. , 2001, Blood.

[5]  A. Levitzki,et al.  Enhanced ROS Production in Oncogenically Transformed Cells Potentiates c-Jun N-Terminal Kinase and p38 Mitogen-Activated Protein Kinase Activation and Sensitization to Genotoxic Stress , 2001, Molecular and Cellular Biology.

[6]  M. Collins,et al.  The JNK phosphatase M3/6 is inhibited by protein-damaging stress , 2001, Current Biology.

[7]  O. Bernard,et al.  Dominant-Negative c-Jun Promotes Neuronal Survival by Reducing BIM Expression and Inhibiting Mitochondrial Cytochrome c Release , 2001, Neuron.

[8]  M. Karin,et al.  Mammalian MAP kinase signalling cascades , 2001, Nature.

[9]  Seth M. Cohen,et al.  Cisplatin: from DNA damage to cancer chemotherapy. , 2001, Progress in nucleic acid research and molecular biology.

[10]  P. Krammer,et al.  The chemotherapeutic drug 5-fluorouracil induces apoptosis in mouse thymocytes in vivo via activation of the CD95(APO-1/Fas) system. , 2001, Cancer research.

[11]  E. Wagner,et al.  The Mammalian UV Response c-Jun Induction Is Required for Exit from p53-Imposed Growth Arrest , 2000, Cell.

[12]  R. Perona,et al.  CL100/MKP-1 modulates JNK activation and apoptosis in response to cisplatin , 2000, Oncogene.

[13]  V. L. Johnson,et al.  MAPK/ERK signaling in activated T cells inhibits CD95/Fas‐mediated apoptosis downstream of DISC assembly , 2000, The EMBO journal.

[14]  P. Krammer,et al.  A Novel AP-1 Element in the CD95 Ligand Promoter Is Required for Induction of Apoptosis in Hepatocellular Carcinoma Cells upon Treatment with Anticancer Drugs , 2000, Molecular and Cellular Biology.

[15]  R. Davis,et al.  Signal Transduction by the JNK Group of MAP Kinases , 2000, Cell.

[16]  D. Bar-Sagi,et al.  Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. , 2000, Science.

[17]  S. Keyse,et al.  Protein phosphatases and the regulation of mitogen-activated protein kinase signalling. , 2000, Current opinion in cell biology.

[18]  N. Farrell,et al.  Platinum-Based Drugs in Cancer Therapy , 2000, Cancer Drug Discovery and Development.

[19]  E. Wagner,et al.  c-Jun-Dependent CD95-L Expression Is a Rate-Limiting Step in the Induction of Apoptosis by Alkylating Agents , 2000, Molecular and Cellular Biology.

[20]  M. Camps,et al.  Dual specificity phosphatases: a gene family for control of MAP kinase function , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  S. Fulda,et al.  Functional CD95 ligand and CD95 death-inducing signaling complex in activation-induced cell death and doxorubicin-induced apoptosis in leukemic T cells. , 2000, Blood.

[22]  R. Perona,et al.  Lack of c‐Jun activity increases survival to cisplatin , 1999, FEBS letters.

[23]  M. Cobb,et al.  MAP kinase pathways. , 1999, Progress in biophysics and molecular biology.

[24]  E. Wagner,et al.  Amino-terminal phosphorylation of c-Jun regulates stress-induced apoptosis and cellular proliferation , 1999, Nature Genetics.

[25]  M. Pincus,et al.  Regulation of JNK signaling by GSTp , 1999, The EMBO journal.

[26]  D. Green,et al.  Withdrawal of Survival Factors Results in Activation of the JNK Pathway in Neuronal Cells Leading to Fas Ligand Induction and Cell Death , 1999, Molecular and Cellular Biology.

[27]  John Calvin Reed.  Mechanisms of apoptosis avoidance in cancer. , 1999, Current opinion in oncology.

[28]  G. Koretzky,et al.  Stress-Induced Fas Ligand Expression in T Cells Is Mediated through a MEK Kinase 1-Regulated Response Element in the Fas Ligand Promoter , 1998, Molecular and Cellular Biology.

[29]  G. Evan,et al.  A matter of life and cell death. , 1998, Science.

[30]  T. Hunter,et al.  Lasting N-Terminal Phosphorylation of c-Jun and Activation of c-Jun N-Terminal Kinases after Neuronal Injury , 1998, The Journal of Neuroscience.

[31]  S. Srinivasula,et al.  Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. , 1998, Molecular cell.

[32]  Jiahuai Han,et al.  Cardiac Hypertrophy Induced by Mitogen-activated Protein Kinase Kinase 7, a Specific Activator for c-Jun NH2-terminal Kinase in Ventricular Muscle Cells* , 1998, The Journal of Biological Chemistry.

[33]  D. Green,et al.  DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. , 1998, Molecular cell.

[34]  R. Perona,et al.  Cisplatin induces a persistent activation of JNK that is related to cell death , 1998, Oncogene.

[35]  L. Rubin,et al.  Phosphorylation of c-Jun Is Necessary for Apoptosis Induced by Survival Signal Withdrawal in Cerebellar Granule Neurons , 1998, The Journal of Neuroscience.

[36]  D. Green,et al.  The c-Jun N-terminal kinase cascade plays a role in stress-induced apoptosis in Jurkat cells by up-regulating Fas ligand expression. , 1998, Journal of immunology.

[37]  M. Karin,et al.  Cooperation between Syk and Rac1 leads to synergistic JNK activation in T lymphocytes. , 1998, Immunity.

[38]  D. Green,et al.  Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD‐specific caspase activation and independently of mitochondrial transmembrane depolarization , 1998, The EMBO journal.

[39]  M. Karin,et al.  Molecular cloning and characterization of human JNKK2, a novel Jun NH2-terminal kinase-specific kinase , 1997, Molecular and cellular biology.

[40]  S. Srinivasula,et al.  Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade , 1997, Cell.

[41]  Xiaodong Wang,et al.  Apaf-1, a Human Protein Homologous to C. elegans CED-4, Participates in Cytochrome c–Dependent Activation of Caspase-3 , 1997, Cell.

[42]  R. Davis,et al.  Mitogen-activated protein kinase kinase 7 is an activator of the c-Jun NH2-terminal kinase. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[43]  O. Potapova,et al.  The Jun Kinase/Stress-activated Protein Kinase Pathway Functions to Regulate DNA Repair and Inhibition of the Pathway Sensitizes Tumor Cells to Cisplatin* , 1997, The Journal of Biological Chemistry.

[44]  M. Su,et al.  Role of p38 and JNK mitogen-activated protein kinases in the activation of ternary complex factors , 1997, Molecular and cellular biology.

[45]  B. Neel,et al.  Protein tyrosine phosphatases in signal transduction. , 1997, Current opinion in cell biology.

[46]  S. Chaney,et al.  DNA damage inducible-gene expression following platinum treatment in human ovarian carcinoma cell lines , 1996, Cancer Chemotherapy and Pharmacology.

[47]  T. Chambers,et al.  Role of the Stress-activated/c-Jun NH2-terminal Protein Kinase Pathway in the Cellular Response to Adriamycin and Other Chemotherapeutic Drugs* , 1996, The Journal of Biological Chemistry.

[48]  M. Karin,et al.  Three distinct signalling responses by murine fibroblasts to genotoxic stress , 1996, Nature.

[49]  R. Weichselbaum,et al.  Activation of p38 Mitogen-activated Protein Kinase by c-Abl-dependent and -independent Mechanisms* , 1996, The Journal of Biological Chemistry.

[50]  Xiaodong Wang,et al.  Induction of Apoptotic Program in Cell-Free Extracts: Requirement for dATP and Cytochrome c , 1996, Cell.

[51]  I. Herr,et al.  Involvement of the CD95 (APO–1/Fas) receptor/ligand system in drug–induced apoptosis in leukemia cells , 1996, Nature Medicine.

[52]  L. Zon,et al.  The stress-activated protein kinase pathway mediates cell death following injury induced by cis-platinum, UV irradiation or heat , 1996, Current Biology.

[53]  R. Treisman,et al.  Regulation of transcription by MAP kinase cascades. , 1996, Current opinion in cell biology.

[54]  L. Zon,et al.  Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis , 1996, Nature.

[55]  R. Davis,et al.  MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway , 1996, Molecular and cellular biology.

[56]  Michael E. Greenberg,et al.  Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis , 1995, Science.

[57]  R. Weichselbaum,et al.  Activation of the c-Abl tyrosine kinase in the stress response to DMA-damaging agents , 1995, Nature.

[58]  L. Rubin,et al.  A c-jun dominant negative mutant protects sympathetic neurons against programmed cell death , 1995, Neuron.

[59]  A. Khokhar,et al.  Biochemical pharmacology of homologous alicyclic mixed amine platinum(II) complexes in sensitive and resistant tumor cell lines. , 1994, Cancer research.

[60]  M. Karin,et al.  Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. , 1993, Genes & development.

[61]  E. Wagner,et al.  c-Jun is essential for normal mouse development and hepatogenesis , 1993, Nature.

[62]  A. Pa,et al.  Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. , 1990 .

[63]  D. Hamer,et al.  Overexpression of metallothionein confers resistance to anticancer drugs. , 1988, Science.

[64]  Z. Siddik,et al.  Flameless atomic absorption spectrophotometric determination of platinum in tissues solubilized in hyamine hydroxide. , 1987, Analytical biochemistry.